Our Pricing

How to Switch from Wegovy to Mounjaro in the UK: A Pharmacist's Guide

Published: 26 August 2026

Understanding how to switch from wegovy to mounjaro uk requires careful consideration of dosing protocols, timing, and prescriber approval. As a UK-registered pharmacy with thousands of weight loss patients under our care, we've guided many individuals through this transition safely and effectively. This comprehensive guide explains the clinical steps, regulatory requirements, and practical considerations for switching from semaglutide to tirzepatide treatment in the UK.

Why Patients Consider How to Switch from Wegovy to Mounjaro UK

Many patients explore how to switch from wegovy to mounjaro uk after achieving initial weight loss on semaglutide but seeking enhanced results. Clinical trial data shows tirzepatide (Mounjaro) delivered average weight reductions of 15-22.5% in the SURPASS-1 trial, compared to semaglutide's 10-15% in the STEP trials [1]. This dual GIP/GLP-1 receptor mechanism may offer additional metabolic benefits for some individuals.

Other common reasons for switching include plateau effects after prolonged Wegovy use, better tolerability profiles with tirzepatide reported by some patients, or supply chain considerations in the UK market. It's essential to understand that switching between GLP-1 based therapies requires prescriber oversight, as both medications work through similar pathways and require careful dose titration [2].

Clinical Protocol for How to Switch from Wegovy to Mounjaro UK

The safest approach for how to switch from wegovy to mounjaro uk involves a structured transition overseen by a UK-registered prescriber. Current clinical guidance suggests discontinuing Wegovy and beginning Mounjaro at its lowest starting dose of 2.5mg weekly, regardless of your previous Wegovy dose [3]. This conservative approach minimises gastrointestinal side effects and allows your body to adjust to tirzepatide's dual-receptor mechanism.

There is no mandatory washout period required when switching from Wegovy to Mounjaro, as both medications have similar half-lives of approximately one week. Most prescribers recommend starting Mounjaro within 7 days of your last Wegovy injection to maintain therapeutic continuity. However, individual circumstances such as side effect history or concurrent medications may influence this timing, which is why prescriber consultation is mandatory under MHRA regulations.

Dose Escalation Schedule After Switching

After initiating Mounjaro at 2.5mg weekly, the standard UK dose escalation follows a 4-week interval protocol: 2.5mg for 4 weeks, then 5mg for 4 weeks, then 7.5mg, 10mg, 12.5mg, and finally 15mg if clinically appropriate [4]. This gradual increase allows tolerance to develop and reduces the risk of nausea, vomiting, and diarrhoea commonly associated with GLP-1 receptor agonists. Your prescriber will assess weight loss progress and tolerability at each stage before authorising dose increases.

Prescriber Requirements for How to Switch from Wegovy to Mounjaro UK

Understanding how to switch from wegovy to mounjaro uk includes recognising that both medications are prescription-only medicines (POMs) regulated by the MHRA. You cannot simply purchase Mounjaro without a new clinical assessment, even if you have an existing Wegovy prescription. At Cured Pharmacy, our UK-registered clinical team conducts a comprehensive online consultation reviewing your medical history, current medications, weight loss progress, and any side effects experienced on Wegovy.

The assessment typically takes under 3 minutes and evaluates contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every prescription meets NICE guidance and MHRA safety standards before dispensing. Approval is subject to clinical suitability, and not all patients will be appropriate candidates for switching.

Timing Considerations for How to Switch from Wegovy to Mounjaro UK

Optimal timing for how to switch from wegovy to mounjaro uk depends on your current Wegovy dose and treatment duration. Patients on lower Wegovy doses (0.25mg-1mg weekly) may find the transition smoother, as the receptor saturation is less pronounced. Those on the maximum 2.4mg Wegovy dose should expect a temporary reduction in GLP-1 receptor activation when starting Mounjaro 2.5mg, though the addition of GIP receptor agonism may offset this [5].

If you've experienced significant side effects on Wegovy, particularly persistent nausea or gastrointestinal disturbances, some prescribers recommend a brief 1-2 week break before initiating Mounjaro to allow symptom resolution. Conversely, if weight loss has plateaued but tolerance is good, immediate switching maintains momentum. Clinical judgement by your prescriber is essential for personalised timing recommendations.

Managing Side Effects During the Transition

When learning how to switch from wegovy to mounjaro uk, anticipate potential side effects similar to your initial Wegovy experience: nausea, reduced appetite, occasional vomiting, diarrhoea, or constipation. These typically peak during the first 4-8 weeks as your body adjusts to tirzepatide. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can mitigate symptoms. If side effects become severe or persist beyond 8 weeks, consult your prescriber for dose adjustment or alternative strategies.

Cost and Availability for How to Switch from Wegovy to Mounjaro UK

When considering how to switch from wegovy to mounjaro uk, cost is a practical factor for many patients. Mounjaro is available at Cured Pharmacy from £124.99 per 4-week supply, with transparent upfront pricing displayed before your clinical consultation. We guarantee the lowest UK prices and offer £20 off your first order with code Weightlossnew, bringing your initial month to £124.99. This competitive pricing ensures affordability does not become a barrier to optimal weight loss treatment.

Unlike some UK pharmacies that require lengthy consultations or unclear pricing structures, Cured Pharmacy provides a streamlined 3-minute online assessment with same-day prescriber review where clinically appropriate. All Mounjaro supplied is genuine UK-licensed tirzepatide manufactured by Eli Lilly, dispensed in discreet packaging with next-day delivery options available. Our GPhC-registered pharmacy (9012511) ensures full regulatory compliance and medication authenticity.

Expected Outcomes When You Switch from Wegovy to Mounjaro UK

Patients often ask what results to expect after learning how to switch from wegovy to mounjaro uk. Clinical data suggests tirzepatide may deliver additional weight loss beyond semaglutide's effects, with SURPASS-2 trial participants losing an average of 5-7kg more on tirzepatide 15mg compared to semaglutide 1mg over 40 weeks [6]. However, individual responses vary significantly based on adherence, lifestyle modifications, baseline weight, and metabolic factors.

It's important to maintain realistic expectations during the transition period. The first 8-12 weeks on Mounjaro involve dose escalation, and substantial weight loss typically accelerates once therapeutic doses (10mg or higher) are reached. Combining medication with a structured nutrition plan and regular physical activity optimises outcomes. Our clinical team provides ongoing support throughout your treatment journey, with regular check-ins to monitor progress and adjust treatment as needed.

Long-Term Considerations and Monitoring

Successful long-term weight management after switching from Wegovy to Mounjaro requires ongoing prescriber monitoring. UK guidelines recommend regular assessment of weight loss progress, side effect profiles, and metabolic markers such as HbA1c and lipid panels where clinically indicated [7]. If weight loss stalls or side effects become problematic, your prescriber may adjust dosing, recommend treatment pauses, or explore alternative options. Sustainability is key—both medications are intended for long-term use alongside lifestyle modifications, not as short-term solutions.

Scientific References

1. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 26 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 26 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. UK Government. [accessed 26 August 2026]
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes: Technology appraisal guidance [TA924]. NICE. [accessed 26 August 2026]
5. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, phase 3 trial. The Lancet, 398(10303), 701-713. [accessed 26 August 2026]
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 26 August 2026]
7. Royal Pharmaceutical Society. (2023). Professional guidance on the supply of GLP-1 receptor agonists for weight management. RPS. [accessed 26 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 26 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 26 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 26 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.